Ausgabe 4/2022
Inhalt (10 Artikel)
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
Bruno Almeida Costa, Tarek H. Mouhieddine, Joshua Richter
Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C Adams III, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry
Camille Verry, Sébastien Vincendeau, Marc Massetti, Martin Blachier, Alexandre Vimont, Marie-Laure Bazil, Pauline Bernardini, Ségolène Pettré, Marc-Olivier Timsit
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index
Ana Ortega-Franco, Clare Hodgson, Haseem Raja, Mathew Carter, Colin Lindsay, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Yvonne Summers, Fiona Blackhall, Raffaele Califano
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
Marco Maruzzo, Francesco Pierantoni, Alberto Bortolami, Dario Palleschi, Andrea Zivi, Maurizio Nicodemo, Donata Sartori, Rocco De Vivo, Fable Zustovich, Davide Bimbatti, Davide Pastorelli, Giuseppe Dione Vultaggio, Mariella Soraru’, Melissa Ballestrin, Caterina Modonesi, Paola Randisi, Carmen Barile, Gino Perri, Umberto Basso, Vittorina Zagonel
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria
Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
Elaine S. Tan, Wenyi Fan, Todd C. Knepper, Michael J. Schell, Ibrahim H. Sahin, Jason B. Fleming, Hao Xie
Comment on: “Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy”
Yusuf Ziya Şener, Salome Begijanashvili
Author’s Reply to Şener and Begijanashvili: “Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy”
Iris Y. Sheng, Alok A. Khorana